Delving into the Latest Updates on Gallium Maltolate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

RNRs

Action

inhibitors

Mechanism

RNR inhibitors(Ribonucleotide reductase inhibitors)

Therapeutic Areas

NeoplasmsNervous System DiseasesOther Diseases

Active Indication

Teratoid Tumor, AtypicalGlioblastoma Multiforme

Inactive Indication

Bacterial InfectionsBladder CancerCastration-Resistant Prostatic Cancer+ [4]

Originator Organization

Titan Pharmaceuticals, Inc.

Active Organization

Imaging Biometrics LLC

Inactive Organization

Titan Pharmaceuticals, Inc.

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC18H15GaO9

InChIKeyASYYOZSDALANRF-UHFFFAOYSA-K

CAS Registry108560-70-9

This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment. This dosing cycle will be repeated. Adverse effects will be assessed and the levels of gallium in serum will be measured. Any effect of the drug on the cancer and any improvement in cancer-related symptoms will also be measured.

Start Date01 Jun 2001

Sponsor / Collaborator

Titan Pharmaceuticals, Inc.

NCT06404034

/ AvailableNot Applicable

Expanded Access to Gallium Maltolate (GaM) for Adult Patients With Relapsed/Refractory Histologic or Molecular Glioblastoma

The objective of this program is to provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments.
The population of this program is adult patients aged greater than or equal to 18 years with a diagnosis of relapsed/refractory histologic or molecular glioblastoma, according to the WHO 2021 diagnostic criteria.
Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes

Start Date-

Sponsor / Collaborator

Imaging Biometrics LLC

[+1]

100 Clinical Results associated with Gallium Maltolate

Login to view more data

100 Translational Medicine associated with Gallium Maltolate

Login to view more data

100 Patents (Medical) associated with Gallium Maltolate

Login to view more data

60

Literatures (Medical) associated with Gallium Maltolate

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Identification and characterization of tubulin as Ga(III)-binding protein in T24 cells

Article

Author: Jia, Shuaile ; Zhang, Shuo ; Yang, Xue ; Wang, Yuchuan ; Chen, Junxin

Gallium-based metallic drugs and agents have been widely applied for the diagnosis and treatment of diseases such as non-Hodgkin's lymphoma (NHL), but there are few reports on the potential Ga(III)-binding proteins and the related cytotoxic mechanisms for Ga(III). Herein, by using human urinary bladder cancer T24 cells as a model, we identify and report that tubulin is a Ga(III)-binding protein target in T24 cells. Our analyses, including the employment of a series of methods based on immobilized metal affinity chromatography (IMAC), cellular thermal shift assay (CETSA), and immunofluorescence experiments, collectively explained this finding. Our results suggest that the binding of Ga(III) to tubulin led to significant changes in the morphology and distribution of microtubules in cells. The blocked microtubule formation or microtubule depolymerization as a result of the binding of Ga(III) to tubulin may be an important molecular mechanism by which Ga(III) exerts its cytotoxic effects in T24 cells to inhibit tumor cell growth.

01 Dec 2024·Bioactive Materials

Antimicrobial hydrogel foam dressing with controlled release of gallium maltolate for infection control in chronic wounds

Article

Author: Fletcher, Alan ; Bryan, Laura ; Welch, Shannara ; Cosgriff-Hernandez, Elizabeth ; Lan, Ziyang ; Ang, Nicolai ; Whitfield-Cargile, Canaan ; Richardson, Lauren ; Guo, Leopold

Effective treatment of infection in chronic wounds is critical to improve patient outcomes and prevent severe complications, including systemic infections, increased morbidity, and amputations. Current treatments, including antibiotic administration and antimicrobial dressings, are challenged by the increasing prevalence of antibiotic resistance and patients' sensitivity to the delivered agents. Previous studies have demonstrated the potential of a new antimicrobial agent, Gallium maltolate (GaM); however, the high burst release from the GaM-loaded hydrogel gauze required frequent dressing changes. To address this need, we developed a hydrogel foam-based wound dressing with GaM-loaded microspheres for sustained infection control. First, the minimal inhibitory and bactericidal concentrations (MIC and MBC) of GaM against two Staphylococcus aureus strains isolated from chronic wounds were identified. No significant adverse effects of GaM on dermal fibroblasts were shown at the MIC, indicating an acceptable selectivity index. For the sustained release of GaM, electrospraying was employed to fabricate microspheres with different release kinetics. Systematic investigation of loading and microsphere size on release kinetics indicated that the larger microsphere size and lower GaM loading resulted in a sustained GaM release profile over the target 5 days. Evaluation of the GaM-loaded hydrogel dressing demonstrated cytocompatibility and antibacterial activities with a zone of inhibition test. An equine distal limb wound model was developed and utilized to demonstrate the efficacy of GaM-loaded hydrogel foam in vivo. This antimicrobial hydrogel foam dressing displayed the potential to combat methicillin-resistant S. aureus (MRSA) infection with controlled GaM release to improve chronic wound healing.

19 Aug 2024·INORGANIC CHEMISTRY

Implementation of Three Gallium-Based Complexes in the “Trojan Horse” Antibacterial Strategy against A. baumannii: A DFT Approach

Article

Author: Dudev, Todor ; Angelova, Silvia ; Nikolova, Valya ; Yocheva, Lyubima ; Dobrev, Stefan ; Kircheva, Nikoleta

Microorganisms of the ESKAPE group pose an enormous threat to human well-being, thus requiring a multidisciplinary approach for discovering novel drugs that are not only effective but utilize an innovative mechanism of action in order to decrease fast developing resistance. A promising but still hardly explored implementation in the "Trojan horse" antibacterial strategy has been recognized in gallium, an iron mimicry species with no known function but exerting a bacteriostatic/bactericidal effect against some representatives of the group. The study herewith focuses on the bacterium A. baumannii and its siderophore acinetobactin in its two isomeric forms depending on the acidity of the medium. By applying the powerful tools of the DFT approach, we aim to delineate those physicochemical characteristics that are of great importance for potentiating gallium's ability to compete with the native ferric cation for binding acinetobactin such as pH, solvent exposure (dielectric constant of the environment), different metal/siderophore ratios, and complex composition. Hence, the provided results not only furnish some explanation of the positive effect of three Ga³⁺-based anti-infectives in terms of metal cation competition but also shed light on reported in vitro and in vivo observations at a molecular level in regard to gallium's antibacterial effect against A. baumannii.

1

News (Medical) associated with Gallium Maltolate

13 Jul 2023

·www.biospace.com

IQ-AI Announces Orphan Drug Designation for GaM in Pediatric GBM

MILWAUKEE, WI / ACCESSWIRE / July 13, 2023 / Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI)(OTCQB:IQAIF), today announced the U.S. Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for gallium maltolate (GaM) for the treatment of pediatric glioblastoma multiforme (GBM). In February, IB was granted Orphan Drug Designation for adult GBM. The US FDA has since confirmed that the designation granted in February applies to both adult and pediatric GBM patients. GBM is the most common and aggressive primary brain tumor in adults and children. There are currently no effective treatments for pediatric glioblastoma. Oral GaM recently demonstrated significant survival benefit in a pre-clinical study for pediatric GBM. The results of the study, performed in the lab of Dr. Kathleen Schmainda, PhD and led by Dr. Mona Al-Gizawiy, PhD from the Medical College of Wisconsin (MCW), were presented at the 2023 Society of Neuro Oncology (SNO) Pediatric Conference in Washington, DC last month. Median overall survival was more than 2x longer in the group treated with GaM compared to the untreated controls. These promising results, coupled with the easy administration by capsule, make this a very attractive potential treatment option for both pediatric and adult patients. "We are very pleased that the FDA has now confirmed that the orphan drug designation for GaM applies to all GBM populations including pediatric patients," said Trevor Brown, CEO of IQ-AI. About Imaging Biometrics® LLC: IB is a wholly-owned subsidiary of IQ-AI Limited, (LON:IQAI)(OTCQB:IQAIF), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at . Follow IB on Twitter, @IQAI_IB. Contact Information: Michael Schmainda Tel: 262-439-8252 SOURCE: IQ AI Ltd. View source version on accesswire.com:

Orphan DrugClinical Result

100 Deals associated with Gallium Maltolate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Gallium Maltolate	-	DB05420

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 2	United States	Titan Pharmaceuticals, Inc.	01 Jun 2001
Castration-Resistant Prostatic Cancer	Phase 2	United States	Titan Pharmaceuticals, Inc.	01 Jun 2001
Refractory Multiple Myeloma	Phase 2	United States	Titan Pharmaceuticals, Inc.	01 Jun 2001
Humoral Hypercalcemia of Malignancy	Phase 1	United States	Titan Pharmaceuticals, Inc.	-
Osteitis Deformans	Phase 1	United States	Titan Pharmaceuticals, Inc.	-
Teratoid Tumor, Atypical	Preclinical	United States	Imaging Biometrics LLC	05 Oct 2023
Glioblastoma Multiforme	Preclinical	United States	Imaging Biometrics LLC	13 Jul 2023
Bacterial Infections	Preclinical	United States	Titan Pharmaceuticals, Inc.	-
Rheumatoid Arthritis	Preclinical	United States	Titan Pharmaceuticals, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNO2023	Phase 1	Recurrent Glioblastoma	-	Oral Gallium Maltolate 500 mg/day	hwwtyikjex(iqlfiuinuv) = dsqbmxtdlt uflczxlcwh (lpbwkkytyw )	-	10 Nov 2023
				Oral Gallium Maltolate 1,000 mg/day	hwwtyikjex(iqlfiuinuv) = mabsxjovow uflczxlcwh (lpbwkkytyw )
EXTH-21 (SNO2016)	Not Applicable	Glioblastoma	-	Gallium Maltolate	khzzfkiaou(wfparxonao) = significantly lower in treated tumors qzxjnqiacl (zhvpnpndwh ) View more	Positive	07 Nov 2016
				Gallium maltolate (Control (Untreated))